Anixa's CAR-T Therapy Receives WHO Name Approval, Paving Path for Global Adoption

Anixa Biosciences Achieves WHO Approval for CAR-T Therapy Name

In a landmark achievement, Anixa Biosciences, Inc., a prominent biotechnology firm listed on NASDAQ under the ticker ANIX, announced that the World Health Organization (WHO) has approved the international non-proprietary name for its innovative CAR-T therapy. This therapy is specifically targeted at treating recurrent ovarian cancer. The name approved by the WHO is "liraltagene autoleucel," a title that reflects the therapy's focus on the follicle-stimulating hormone receptor, known as FSHR, which is predominantly found in normal ovarian cells and certain cancerous cells. This approval not only signifies a critical milestone for Anixa but also positions them closer to broader global acceptance and potential commercialization of their treatment.

The designation of a non-proprietary name is imperative in the pharmaceutical industry as it ensures guidance for healthcare professionals globally, streamlining the prescription and dispensing processes. As Dr. Amit Kumar, the Chairman and CEO of Anixa, stated, the approval enhances the possibility of establishing a universally recognized name that avoids conflicts and aligns with the regulatory standards set forth by governing bodies in the global healthcare landscape.

In a statement, Dr. Kumar emphasized that this approval is a significant step forward, aiding in the ongoing clinical studies and promoting the advancement of their CAR-T therapy. Currently, the company is progressing in its Phase 1 trial of liraltagene autoleucel, which aims to treat women suffering from recurrent ovarian cancer who have not responded to at least two prior therapies. This trial is being conducted in collaboration with the esteemed Moffitt Cancer Center, a leader in cancer treatment and research.

The Phase 1 study's goals are comprehensive, aiming not only to evaluate the safety of liraltagene autoleucel but also to identify the maximum tolerated dosage and monitor its clinical efficacy. The structure of the therapy is intriguing; it utilizes a CAR-T format distinguished by targeting the FSHR, leveraging the natural interaction between hormones and their receptors to enhance the immune response against cancer cells. This new approach is being branded as chimeric endocrine receptor-T cell therapy (CER-T).

Anixa has a robust pipeline focusing on the field of cancer immunotherapy, which extends beyond ovarian cancer. They have also partnered with the Cleveland Clinic to develop vaccines aimed at preventing breast and ovarian cancers, as well as tackling other high-incidence malignancies such as lung, colon, and prostate cancers through innovative vaccine technologies founded on targeting specific proteins associated with cancer.

Recognizing the uniqueness of its intellectual property, Anixa licenses its CAR-T technology from The Wistar Institute and works in collaboration with distinguished institutions like Moffitt Cancer Center and Cleveland Clinic. Their strategy emphasizes the importance of partnership with leading research entities to propel advancements in cancer treatment.

While Anixa's journey holds potential for revolutionizing treatments for various cancers, the recent WHO approval marks a significant entry point for liraltagene autoleucel into markets requiring a clearer naming structure that aligns with international standards. As the trial progresses and the company moves towards commercialization, the healthcare community and patients alike will watch closely to see this promising therapy's impact on treating recurrent ovarian cancer.

For further details, Anixa invites readers to visit their official website or follow their updates across various social media platforms, which include LinkedIn, X (formerly Twitter), Facebook, and YouTube. This progress is certainly regarded as a beacon of hope in the fight against cancer, showcasing how ongoing research and development can pave the way for more effective treatments and better outcomes for patients battling this disease.